… In 2012, a new human disease called Middle East respiratory syndrome (MERS), having
a high mortality rate, emerged in the Middle East. It was caused by a virus that was originally …

… Further, kinases are the most frequently targeted gene class in cancer therapy, second only
… as therapeutic targets [83, 84]. The therapeutic potential for host-targeted immunomodulatory …

… Host cell proteases are therefore potential molecular therapeutic targets for MERS-CoV
prophylaxis and/or treatment (Fig. 2, Table 1). The TMPRSS2 inhibitor camostat, for example, …

… The pathogenic agent of Middle East respiratory syndrome is … Following that case, another
patient from the Middle East … has spread in countries across Middle East and Europe [Citation7…

Background Pathogenic coronaviruses include Middle East respiratory syndrome coronavirus
(MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and SARS-…

… Most facilities and healthcare providers outside of the Middle East receiving patients have no
… The use of any therapeutics in MERS-CoV remains investigational. The therapeutic agents …

… proteins can act as therapeutic targets, in which various therapeutic options have been
implemented and will be discussed in Sections "Various therapeutic agents against MERS-CoV …

… most of the cases are linked to the Middle East [2]. So far there have … therapy and no
approved therapies for MERS-CoV infection by international or national societies. Few therapeutic …

… of CRC in Middle Eastern populations and genes that could be targeted in cancer therapy,
we … gene on the clinicopathological outcome of Middle Eastern CRC, protein expression of …

… targeted therapy readily available for patients. Deep … Middle East using deep targeted
sequencing. In the present study, we characterized recurrent hot spot mutations in Middle Eastern …